Figure 1: Glycolysis provides cancer cells with energy and biomass production. Most therapies target either hexokinase and its isoforms (hexokinase II being mostly overexpressed in cancer) and lactate dehydrogenase. Targeting the rest of the glycolytic enzymes could be dangerous to the patient as those enzymes are universally expressed. Being the fundamental source of carbon for lactic acid production, inhibiting glycolysis could be assessed by measuring changes in tumor extracellular pH.